This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.

The Epoch Times
The Epoch Times
Focus

CureVac

LATEST

Business
Business
|
Reuters

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims

Sep 05, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims
Sep 05
|
FacebookXTruthGettrLinkedInTelegramEmail
Economy
Economy
|
Reuters

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims

Jul 28, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims
Jul 28
|
FacebookXTruthGettrLinkedInTelegramEmail
Companies
Companies
|
Reuters

CureVac Files Patent Lawsuit in Germany Against BioNTech

Jul 06, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
CureVac Files Patent Lawsuit in Germany Against BioNTech
Jul 06
|
FacebookXTruthGettrLinkedInTelegramEmail
Vaccines & Safety
Vaccines & Safety
|
Reuters

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout

Jul 01, 2021
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout
Jul 01
|
FacebookXTruthGettrLinkedInTelegramEmail
home-iconepochtv-iconhealth-iconbright-iconepochfun-icon
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.